The EU Critical Medicines Act Puts Supply Security Inside Market Access Work

Introduction

Medicine shortages in Europe stopped being an occasional inconvenience sometime around the pandemic years and turned into a recurring structural problem: antibiotics, certain generics, and a handful of hospital-critical drugs repeatedly ran short because too much of their production, especially active pharmaceutical ingredients, was concentrated in a small number of manufacturing sites outside the EU. The European Union's response, the Critical Medicines Act, is working its way through the EU's legislative process and is one of the more consequential pieces of pharmaceutical policy to watch for anyone doing regulatory, quality, or market access work tied to Europe.

As of this writing the Act has moved through most of the ordinary legislative procedure but has not completed every formal step: the Council reached a general approach in December 2025, the European Parliament adopted its negotiating position in January 2026, and the Commission announced a political agreement reached in trilogue talks in May 2026. Formal adoption by Parliament and Council and publication in the Official Journal, the steps that would set a confirmed entry-into-force date, were still pending at last check. Anyone relying on this for compliance planning should confirm the current status directly through the European Commission, EMA, or the EU's legislative observatory rather than a secondary source, since details can still shift before final text is published.

The Problem It's Trying to Solve

The EU built a "critical medicines" shortage-monitoring list years ago, identifying medicines whose unavailability would have a significant impact on healthcare systems. What that list exposed, repeatedly, was a structural vulnerability: for many of these medicines, especially older generics and APIs, global manufacturing capacity is concentrated in a small number of sites, often outside Europe, with little redundancy. A single plant shutdown, a quality failure, or a geopolitical disruption can ripple into continent-wide shortages of medicines that are cheap, essential, and otherwise unremarkable.

The Critical Medicines Act is explicitly modeled on the EU's earlier Critical Raw Materials Act, which took a similar approach to materials like lithium and rare earth elements: identify what's critical, diversify where it comes from, and use the weight of EU procurement and investment policy to encourage production closer to home rather than relying purely on market forces to fix the concentration problem.

What the Act Actually Does

Based on the text as negotiated through trilogue, the core mechanisms include:

• A Union list of critical medicines, building on the existing shortage-monitoring list but intended to anchor the Act's other provisions, such as procurement preferences and strategic project status, to a defined and periodically updated set of medicines.
• Procurement criteria that favor supply security, allowing public tenders and joint procurement to weight diversification of supply and EU-based manufacturing alongside price, rather than awarding contracts on price alone.
• "Strategic project" status for qualifying manufacturing investments, intended to speed up permitting and improve access to funding for companies building or expanding EU production capacity for critical medicines or their ingredients.
• Stockpiling and earlier shortage reporting obligations, requiring manufacturers to notify authorities of anticipated supply disruptions earlier than existing shortage-notification rules require, giving health systems more lead time to respond.
• Coordination mechanisms between the Commission, EMA, and member state authorities intended to align national stockpiling and shortage-response efforts that have historically operated largely independently of each other.

None of this replaces the existing marketing authorization and GMP compliance framework; it layers a supply-security and procurement policy on top of it, aimed specifically at structural shortage risk rather than product safety or efficacy. A medicine can be perfectly safe, effective, and fully compliant with every existing quality requirement and still qualify as critical under this framework simply because too few sites in the world can make it.

What Changes for the People Who Do This Work

For regulatory affairs, the most direct impact is on shortage reporting: earlier notification triggers mean regulatory and supply chain teams need tighter internal processes for flagging anticipated disruptions well before they become acute, rather than reporting once a shortage is already visible. For market access and government affairs professionals, the procurement provisions matter enormously: a tender that weights diversified or EU-based supply changes how a company positions a bid, and someone needs to understand both the commercial case and the compliance mechanics of qualifying for that preference.

For manufacturers considering new or expanded EU capacity, qualifying for strategic project status becomes a genuine commercial consideration, which creates new work translating what are essentially policy eligibility criteria into a company's investment and regulatory planning. And for quality and supply chain teams generally, the Act's emphasis on diversified sourcing pushes companies to document and justify their supply chain resilience in ways that go beyond traditional supplier qualification audits.

None of this is a single new job title so much as a new set of requirements layered onto existing regulatory affairs, market access, and supply chain roles, which is exactly how shortage-related rules have landed in Europe before. People who understand both the compliance mechanics and the commercial stakes, able to translate a procurement preference into an actual bid strategy, are likely to find this expertise genuinely scarce in the near term, simply because the rules are new enough that almost no one has deep hands-on experience with them yet.

How This Compares to Existing EU Shortage Rules

The EU already requires marketing authorization holders to notify national authorities of anticipated supply disruptions under existing pharmaceutical legislation, and the European Medicines Agency already coordinates shortage monitoring for certain centrally authorized and critical products through mechanisms built up since the pandemic. The Critical Medicines Act doesn't discard any of that; it extends the notification timeline earlier, formalizes the critical medicines list the existing monitoring work already relies on, and, most significantly, adds the procurement and investment incentive layer that previous shortage rules never included. Earlier shortage rules focused almost entirely on transparency and reporting. This one is the first to directly use the EU's purchasing power and investment policy to try to change where manufacturing actually happens.

What to Watch For

Because the Act had not completed final adoption as of this writing, several practical details remain open: the exact composition and update cadence of the Union critical medicines list, the specific weighting procurement authorities will be allowed or required to give to supply security criteria, and the transition timeline between publication and the point at which reporting and procurement obligations actually bind companies. Professionals tracking this should follow the European Commission's pharmaceutical strategy pages, EMA's shortages and availability communications, and the EU legislative observatory's record for procedure 2025/0102(COD) rather than treat any single news summary, including this one, as the final word on mechanics that may still be adjusted before formal publication.

How Companies Are Likely to Prepare

Even before final text is published, the direction of the Act is clear enough that several preparatory moves are low-regret regardless of exactly how the details land. Companies with manufacturing or sourcing tied to medicines likely to appear on an expanded critical list are starting to map their own supply chains against diversification criteria now, rather than waiting for a tender to ask the question. Government affairs and market access teams are building internal fluency in how strategic project status might apply to planned capacity investments, since permitting and funding processes tend to move on timelines measured in years, not months, and waiting for final adoption to start that conversation internally would cost real time. And regulatory and supply chain functions that currently treat shortage notification as a compliance checkbox are beginning to build the earlier-warning internal processes the Act is expected to require, partly because doing so is good practice regardless of the exact legal trigger date.

This pattern, treating a not-yet-final EU regulation's clear direction as a planning signal rather than waiting for the Official Journal, is a familiar one in life sciences regulatory affairs. Companies that waited for final MDR or IVDR text before beginning technical file remediation work, for comparison, generally regretted the delay once transition deadlines arrived faster than expected.

It's also worth being honest about the limits of this kind of policy lever. Procurement preferences and strategic project status can tilt where new manufacturing investment lands and can speed up permitting for projects already being considered, but they don't, by themselves, make EU manufacturing cost-competitive with lower-cost regions overnight. The Act is best understood as one tool among several, alongside national industrial policy, EU structural funds, and ordinary commercial incentives, rather than a single mechanism that resolves supply concentration on its own. Professionals advising on this should be careful not to oversell what procurement weighting alone can achieve.

Conclusion

The Critical Medicines Act is less a single compliance deadline to prepare for and more a signal of where EU pharmaceutical policy is heading: treating manufacturing location and supply diversification as a procurement and investment lever, not just a shortage-reporting exercise. For regulatory, market access, and supply chain professionals working in or with the EU, the practical move right now is less about mastering final mechanics that haven't been published yet and more about understanding the direction clearly enough to recognize the new requirements, and the new opportunities, as they land over the next couple of years.